Engineers Gate Manager LP Sells 81,590 Shares of Edwards Lifesciences Corporation $EW

Engineers Gate Manager LP cut its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 37.3% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 137,294 shares of the medical research company’s stock after selling 81,590 shares during the period. Engineers Gate Manager LP’s holdings in Edwards Lifesciences were worth $12,420,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Hanson & Doremus Investment Management purchased a new position in shares of Edwards Lifesciences during the 1st quarter valued at about $25,000. JPL Wealth Management LLC purchased a new stake in Edwards Lifesciences in the 3rd quarter worth approximately $25,000. MV Capital Management Inc. purchased a new stake in Edwards Lifesciences in the 4th quarter worth approximately $26,000. RMG Wealth Management LLC bought a new stake in Edwards Lifesciences during the 1st quarter worth approximately $26,000. Finally, Pin Oak Investment Advisors Inc. bought a new stake in Edwards Lifesciences during the 2nd quarter worth approximately $26,000. Institutional investors own 79.46% of the company’s stock.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, SVP Andrew M. Dahl sold 544 shares of the firm’s stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $91.06, for a total transaction of $49,536.64. Following the completion of the transaction, the senior vice president owned 14,868 shares in the company, valued at $1,353,880.08. This trade represents a 3.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, VP Annette Brüls sold 2,644 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $89.98, for a total value of $237,907.12. Following the completion of the sale, the vice president directly owned 17,984 shares in the company, valued at approximately $1,618,200.32. The trade was a 12.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 5,045 shares of company stock valued at $457,749. Insiders own 0.31% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of NYSE EW opened at $86.69 on Friday. The company has a market cap of $49.92 billion, a P/E ratio of 49.82, a P/E/G ratio of 2.26 and a beta of 0.85. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $96.29. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. The firm’s fifty day moving average is $89.36 and its two-hundred day moving average is $85.80.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.74 by $0.04. The business had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The business’s revenue was up 13.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have weighed in on EW. JPMorgan Chase & Co. upped their price target on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research report on Friday, July 24th. TD Cowen restated a “buy” rating on shares of Edwards Lifesciences in a research report on Tuesday, July 21st. Evercore reaffirmed an “outperform” rating and issued a $100.00 target price on shares of Edwards Lifesciences in a report on Monday, July 6th. Truist Financial increased their price target on Edwards Lifesciences from $90.00 to $95.00 and gave the stock a “hold” rating in a research note on Thursday, July 16th. Finally, Mizuho lifted their target price on Edwards Lifesciences from $100.00 to $105.00 and gave the company an “outperform” rating in a research note on Wednesday, July 15th. Seventeen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $100.27.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease. Its products are designed to treat conditions affecting the heart valves and related cardiovascular structures, helping patients with diseases such as aortic stenosis, mitral regurgitation and tricuspid valve disorders.

The company’s portfolio includes transcatheter aortic valve replacement systems, including its SAPIEN platform, as well as transcatheter mitral and tricuspid therapies and surgical heart valve products.